ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,306.04
0.02%
US Tech 100
18,387.60
0.38%
Dow Jones
38,852.86
-0.55%
Brent Oil
84.165
-0.19%
Bitcoin
68,741.37
0.66%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kyverna Therapeutics Inc (KYTX) Quote

Kyverna Therapeutics Inc

Kyverna Therapeutics Inc (KYTX)

NASDAQ
13.23
0.23
(1.77%)
Closed May 28 4:00PM
Delayed by 15 minutes
13.215
-0.015
(-0.11%)
After Hours: 7:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
13.23
Bid
10.01
Ask
20.66
Volume
403,437
12.82 Day's Range 13.72
12.15 52 Week Range 35.01
Market Cap
539.266M
Previous Close
13.00
Open
13.20
Last Trade
623
@
13.23
(priorref)
Last Trade Time
Financial Volume
$ 5,272,597
VWAP
13.0692
Average Volume (3m)
386,251
Shares Outstanding
40,822,525
Dividend Yield
-
PE Ratio
-8.93
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-60.37M

About Kyverna Therapeutics Inc

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin... Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
kyvernatx.com
Headquarters
Dover, Delaware, USA
Founded
1970
Kyverna Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KYTX. The last closing price for Kyverna Therapeutics was $13. Over the last year, Kyverna Therapeutics shares have traded in a share price range of $ 12.15 to $ 35.01.

Kyverna Therapeutics currently has 40,822,525 shares outstanding. The market capitalization of Kyverna Therapeutics is $539.27 million. Kyverna Therapeutics has a price to earnings ratio (PE ratio) of -8.93.

KYTX Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR Newswire EMERYVILLE, Calif., May 14, 2024 Advanced clinical development in two broad areas of...

May 14 2024
PR Newswire (US)

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune...

April 11 2024
PR Newswire (US)

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med PR Newswire EMERYVILLE, Calif., March 29, 2024 Two patients were treated...

March 29 2024
PR Newswire (US)

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results PR Newswire EMERYVILLE, Calif., March 26, 2024 Advanced clinical development in two broad areas of...

March 26 2024
PR Newswire (US)

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis PR Newswire EMERYVILLE, Calif., March 7, 2024 The...

March 07 2024
PR Newswire (US)

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire EMERYVILLE, Calif., Feb. 12, 2024 EMERYVILLE...

February 12 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.99-6.9620253164614.2214.2912.1523473813.16722061CS
4-1.63-10.969044414514.8617.5512.1534277014.70996232CS
12-15.42-53.821989528828.6530.612.1538625120.44324371CS
26-21.02-61.372262773734.2535.0112.1541598022.86518878CS
52-21.02-61.372262773734.2535.0112.1541598022.86518878CS
156-21.02-61.372262773734.2535.0112.1541598022.86518878CS
260-21.02-61.372262773734.2535.0112.1541598022.86518878CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.07M
AWINAERWINS Technologies Inc
$ 8.99
(139.10%)
5.41M
INSMInsmed Inc
$ 48.107
(118.67%)
33.41M
GVVisionary Holdings Inc
$ 0.38
(90.00%)
10.33M
SOBRSOBR Safe Inc
$ 0.41
(82.22%)
130.83M
APDNApplied DNA Sciences Inc
$ 0.580601
(-70.82%)
9.45M
LUCYInnovative Eyewear Inc
$ 0.40
(-59.31%)
84.98M
MRAIMarpai Inc
$ 0.90
(-53.61%)
803.83k
TOIIWOncology Institute Inc
$ 0.021
(-52.60%)
293.22k
SHOTWSafety Shot Inc
$ 0.21
(-36.07%)
24.26k
PEGYPineapple Energy Inc
$ 0.2595
(45.70%)
676.58M
GWAVGreenwave Technology Solutions Inc
$ 0.0782
(-7.89%)
306.52M
STSSSharps Technology Inc
$ 0.5289
(146.80%)
302.07M
CRKNCrown Electrokinetics Corporation
$ 0.1073
(6.24%)
232.53M
OBLGOblong Inc
$ 0.21
(19.32%)
146.15M

Discussion

View Full Feed
JMarv JMarv 3 minutes ago
Long in disguise
NWBO
dannyzee84 dannyzee84 4 minutes ago
Futures bleeding out, might be blood in the streets at tomorrows open
Zorax Zorax 4 minutes ago
I wonder what her "community service" will be.

Working prison law instruction with hewhoshitsinpants and cronies.
J_Dean J_Dean 5 minutes ago
What’s your LTC price prediction 2024?
LTC
badgerkid badgerkid 5 minutes ago
45 ATCs currently listed at this moment (5/28/24 10 pm CDT). 50 before the end of the week? That was the statement today in the chat.

Good luck to Iovance as they ramp-up at lightening speed. If they keep executing the plan they laid out, the stock price will certainly correct to
IOVA
Gusher405 Gusher405 6 minutes ago
Nope. Although when this hits may need to get a suitcase!

Lets GO DBMM!
DBMM
janice shell janice shell 6 minutes ago
Tell me, ALDRADJKD. What's your family's ethnicity? Where did you come from, and when?

Do you know what "nation of immigrants" means?
4Duxs 4Duxs 7 minutes ago
1,500 KQ’s.
LEHNQ
Zorax Zorax 8 minutes ago
Wrong board. All members can contact admin for free.
You could ask that member to come here and have it out here.
bull runs bull runs 8 minutes ago
Actor Dennis Quaid is ready to MAGA, will vote Trump
DJT
WALL STREET KID WALL STREET KID 9 minutes ago
🔥🩳🔥 Tomorrow is T+1 settlement 👀

For shorts hedge funds :

Good points :

- faster position adjustment
- decreased contreparty risk

Bad points :

- collateral management
- increas
AMC
getmoreshares getmoreshares 9 minutes ago
/EINPresswire.com/
https://www.einpresswire.com/article/713854324/a-r-t-digital-holdings-announces-filing-of-q1-2024-financials-corporate-update
CGAC
Whalatane Whalatane 10 minutes ago
CMO also buying https://ih.advfn.com/stock-market/NASDAQ/rezolute-RZLT/stock-news/93936221/form-4-statement-of-changes-in-beneficial-owners

Kiwi
RZLT
nnvcfan nnvcfan 10 minutes ago
With the rise AI, what corruptions in the market cannot be traced and fixed? SEC thought too much about itself!
NSAV
govprs govprs 11 minutes ago
Indicates current situation maybe short term impact. What is short term? Who the heck knows.
GDVM
Kmacneill116 Kmacneill116 12 minutes ago
Dues time homie. We are good at some point. I do believe in the business. We will see grey starts happening that dilution most of the time and we havnt had much of that lately. Need that update no grey days $$$
RNVA
hweb2 hweb2 12 minutes ago
Hope it works out on IPW. Seems strange you're buying back in after this post a few days ago. It's even higher now...and more of a gamble!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174486623

I think IPW is benefiting from the current frothiness on
FFIE IPW
bull runs bull runs 12 minutes ago
As I said at least there’s hope for future generations. Universities will be cleaned of leftists commies who have INDOCTRINATED the likes of you.
DJT
chrispy2468 chrispy2468 12 minutes ago
Ah. Ihub jail, I thought you said regular jail. I was like ,,,what??
GBTC
Drinkley Czarnecki Drinkley Czarnecki 13 minutes ago
Does anyone know the group number of our forum? If there is no pure stock group, I recommend a stock group without junk information and arguments, share stock information every day, and the most important thing is to recommend one or two high-quality stocks to make money for everyone every week (exp
NB
Hoghead7 Hoghead7 14 minutes ago
42 modules $160M 6 modules in 24, 30 in 25 and remaining 6 in 26. Approximately $23M in 24, and $115M in 25. Previous estimates for 25 were $300M in certain based on knowledge of $100+M from SK expected. Now add $10+M from Exxonmobil, add at least $1M from other advanced tech and $63M from Genera
FCEL
JohnnyBlaze JohnnyBlaze 14 minutes ago
Nice
GVDI
Zorax Zorax 14 minutes ago
Everyday we’re getting closer to greatness Wonder which uhp employee this one is.
UEEC

Your Recent History

NASDAQ
KYTX
Kyverna Therapeutics
LSE
BOOM
Audioboom
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved